FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
Interagency Meeting
March 13, 2025
AGENDA

Topic: To discuss and make recommendations on the strain composition of influenza virus vaccines for use in United States during the 2025-2026 influenza season.

Attendees:

Center for Biologics Evaluation and Research (CBER/FDA): Sudhakar Agnihothram, Karin Bok, Robert Daniels, Maryna Eichelberger, Manju Joshi, David C. Kaslow, Peter Marks, Julie Tierney, Jerry Weir, and Zhiping Ye

Centers for Disease Control and Prevention (CDC): Vivien Dugan, Lisa Grohskopf, and Rebecca Kondor

Department of Defense (DoD): Anthony Fries, Shayne Gallaway

Time	Presentation/Presenter
9:00am – 9:05am	**Opening Remarks (5 Min)** **David C. Kaslow, M.D.** (Meeting Chair) Director, Office of Vaccines Research and Review (OVRR) CBER, FDA
9:05am – 9:20am	**Introduction (15 Min including Q&A)** **Jerry Weir, Ph.D. (10 Min)** Director Division of Viral Products (DVP) OVRR, CBER, FDA Q & A: 5 min
9:20am – 10:05am	**CDC Presentations (45 Min including Q&A)** **U.S. Surveillance** **Lisa Grohskopf, M.D., M.P.H. (10 Min)** Medical Officer Epidemiology & Prevention Branch, Influenza Division CDC
	Global Influenza Virus Surveillance and Characterization **Rebecca G. Kondor, Ph.D. (30 Min)** Lead, Genomic Analysis Team

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Biologics Evaluation and Research (CBER)
Interagency Meeting
March 13, 2025
AGENDA

	NCIRD/Influenza Division/Virology Surveillance and Diagnosis Branch, CDC Q & A: 5 min
10:05am – 10:20am	**<u>DoD Influenza Surveillance and Mid-Season Vaccine Effectiveness (15 Min including Q&A)</u>** **Anthony Fries, Ph.D. (10 Min)** DoD Global Respiratory Pathogen Surveillance Program Lead United States Air Force School of Aerospace Medicine Q & A: 5 min
10:20am – 10:30am	**<u>Candidate Vaccine Strains & Potency Reagents (10 Min including Q&A)</u>** **Manju Joshi, Ph.D. (5 Min)** Lead Biologist Division of Biological Standards & Quality Office of Compliance and Biologics Quality CBER/FDA Q & A: 5 min
10:30am – 11:30am	**Discussion and Recommendation (60 Min)**
11:30am	**Adjourn the Meeting** **Peter Marks, M.D., Ph.D.** Director CBER, FDA